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In this issue ofCancer Cell, Mulero and colleagues describe anNF-kB independent transcriptional repression
function for SUMOylated IkBa. This compelling and provocative model links IkBa to the activity of the
Polycomb repressors and provides a mechanism to link inflammatory signaling to skin homeostasis.A common theme among inducers of the
‘‘classical’’ NF-kB pathway, such as
tumor necrosis factor a (TNF-a), is the
rapid targeting of IkBa for proteasomal
degradation as a consequence of serine
(S) 32/36 phosphorylation resulting in
lysines (K)-48 linked ubiquitylation at K
21/22 (Hayden and Ghosh, 2008). IkBa
removes active NF-kB complexes from
the nucleus of the cell and retains them
in a predominantly cytoplasmic form
(Hayden and Ghosh, 2008). The Hay labo-
ratory first reported a degradation-resis-
tant SUMO-1-modified form of IkBa that
could no longer be ubiquitylated (Desterro
et al., 1998). However, the function and
physiological context of this modification
remained unclear.
In this issue ofCancer Cell, Mulero et al.
(2013) observed that, in contrast to most
tissue types, high levels of nuclear IkBa
were present in basal layer keratinocytes
of human and mouse skin. A variety of
techniques confirmed the specificity of
this signal, but strangely, in western blot
analysis, keratinocyte nuclear IkBa had a
distinct, higher apparent molecular
weight than the ‘‘normal’’ protein. Further
analysis demonstrated that this was an
S32/S36 phosphorylated, K21/K22
SUMOylated form of IkBa (PS-IkBa)
(Mulero et al., 2013). In contrast to the
earlier work of Desterro et al. (1998), PS-
IkBa was found to be modified by
SUMO2/3 but not SUMO1. Further inves-
tigation revealed that nuclear PS-IkBa is
recruited directly to the promoters of
potentially >2,000 target genes. More-
over, PS-IkBa was found to recruit
components of the Polycomb repressor
complex (PRC2), including EZH2 and
SUZ12, to promoters identified by the
ChIP-Seq analysis. Significantly, these
included many known Polycomb targetgenes, such as members of the HOX
and IRX families (Mulero et al., 2013).
These gene targets suggested a poten-
tial role for PS-IkBa in embryonic devel-
opment and differentiation. However,
although the IkBa knockout mouse dies
at day five after birth, this phenotype re-
sults from massive skin inflammation
and can be rescued by crossing onto
TNF null mice, indicating this effect is
not primarily developmental (references
in Mulero et al., 2013). Mulero et al.
(2013) therefore propose that the physio-
logical role of PS-IkBa is to function as
an NF-kB independent TNF effector that
integrates inflammatory signaling with
skin homeostasis (Figure 1). At the molec-
ular level, through PRC2 recruitment,
nuclear PS-IkBa suppresses HOX and
IRX transcription until cells become
exposed to TNF or are induced to differ-
entiate. At this point, through a mecha-
nism that is unclear, PS-IkBa is lost or
degraded, resulting in failure to recruit
PRC2 to these promoters and subse-
quent upregulation of gene expression
(Mulero et al., 2013).
These data help explain another long-
standing enigma in the NF-kB/IkB field,
namely why inhibition of NF-kB in the
skin has a tumor promoting effect. A vari-
ety of tumor promoting and tumor sup-
pressing functions for NF-kB/IkB/IKK
family members have been reported, but
generally, pro-inflammatory NF-kB sig-
naling is associatedwith increased tumor-
igenesis (Perkins, 2012). However, in
murine skin, inhibition of NF-kB through
expression of the so-called super-
repressor (SR) mutant IkBa, in which S32
and S36 are mutated to alanine, results
in squamous cell carcinoma (SCC)-like
tumors (van Hogerlinden et al., 1999).
Moreover, in normal human epidermalCancer Cell 24cells, expression of the IkB SR bypasses
oncogenic H-Ras V12 dependent growth
arrest, resulting in malignant cells resem-
bling SCC (Dajee et al., 2003).
To address this issue, Mulero et al.
(2013) examined the role of PS-IkBa in
H-Ras V12/DNp63a transformation of pri-
mary murine keratinocytes. Interestingly,
keratinocyte transformation was associ-
ated with the loss of PS-IkBa together
with reduced recruitment of PRC2 com-
ponents to IkBa target genes, whose
expression was highly induced. This
correlated with observations from human
skin and SCC, where normal skin or
nonmalignant lesions retained nuclear
IkBa, which was replaced by the cyto-
plasmic form in malignant cancer cells.
Mulero et al. (2013) propose that cyto-
plasmic accumulation of IkBa drives cell
transformation through inhibition of
NF-kB and sequestration of nuclear tran-
scriptional corepressors. SUMOylation
of the PS-IkBa isoform requires S32/S36
phosphorylation, and Mulero et al. (2013)
show that mutation of these sites creates
a form of the protein that is no longer effi-
ciently recruited to chromatin (Mulero
et al., 2013). Therefore, the inability of
IkB SR to repress HOX and IRX genes is
likely to contribute to its ability to induce
tumorigenesis. It is not clear if the IkB
SR has a dominant negative effect on
PS-IkBa function resulting in HOX and
IRX gene upregulation. Although such an
effect would be consistent with the core-
pressor sequestration model presented
by the authors, no data are presented to
confirm this. Nonetheless, these results
sound a cautionary note for the use of
the IkB SR as an experimental tool,
as they suggest its expression may
have consequences distinct from NF-kB
inhibition., August 12, 2013 ª2013 Elsevier Inc. 139
Figure 1. The Balance between Nuclear and Cytoplasmic IkBa
Schematic diagram summarizing some of the main conclusions from Mulero et al. (2013). In unstimulated, basal layer keratinocytes, the phosphorylated and
SUMOylated PS-IkBa form of IkBa is nuclear. Here, it recruits the polycomb repressor complex PRC2 to numerous target genes, including members of the
HOX and IRX family, whose expression is repressed. If the keratinocytes receive an inflammatory signal such as TNF-a or are induced to differentiate, the balance
switches to the cytoplasmic form of IkBa, leading to induction of HOX and IRX genes and regulation of NF-kB activity. Oncogenic transformation by H-Ras V12
can also induce this change, which may also be a consequence of overexpression of the IkB SR protein. The balance between these different forms of IkBa
provides a mechanism to link inflammatory signaling to skin homeostasis.
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PreviewsAs would be expected from a study that
breaks new ground, there remain a num-
ber of unanswered questions and mecha-
nistic uncertainties. The first of these
concerns keratinocytes and why they
possess the nuclear PS-IkBa isoform.
The ‘‘wiring’’ of the NF-kB pathway in
keratinocytes appears distinct to other
cell types. In addition to the observations
discussed above, an NF-kB and kinase
independent requirement for IKK-a in ker-
atinocyte development has been reported
(Hu et al., 2001). It is intriguing to note that
Mulero et al. (2013) found that IKK-a can
induce loss of the PS-IkBa isoform, but
it was not established if this function
requires kinase activity. However,
SUMOylated IkBa is found in many cell
lines and alsomouse fibroblasts (Desterro
et al., 1998; Mulero et al., 2013). Further-
more, adenosine signaling during hypoxia
and reoxygenation can also induce IkBa
SUMOylation (Liu et al., 2009). Therefore,
this may be a more common mechanism
than it appears, although functional
effects in other cell types may be subtler
(or have been overlooked).
Key mechanistic questions remain,
such as the identity of the PS-IkBa S32/
36 kinase. Although the IKK complex usu-
ally phosphorylates these sites, this does
not seem to be the case for the nuclear
PS-IkBa isoform. Indeed, IKK activity
seems to negatively correlate with its
presence (Mulero et al., 2013). Further-
more, the mechanism of PS-IkBa removal
from the chromatin and the nucleus is un-140 Cancer Cell 24, August 12, 2013 ª2013 Eclear but it will be interesting to determine
if this involves TNF-induced SUMO 2/3-
linked ubiquitylation (Aillet et al., 2012).
SUMOylation stabilizes IkBa, prevent-
ing ubiquitin-mediated proteolysis, and it
is proposed that this is its primary role in
PS-IkBa-dependent transcriptional re-
pression. However, SUMOylation is also
linked to active transcriptional repression,
through the recruitment of corepressor
complexes. Indeed. Polycomb proteins
are linked to SUMOylation, and this is
associated with their ability to regulate
gene expression (Garcia-Dominguez and
Reyes, 2009). For example, the Pc2 sub-
unit interacts with Ubc9 and can func-
tion as an E3 SUMO ligase. Moreover,
transcriptional corepressors, such as
HDAC1, contain SUMO interacting motifs
(Garcia-Dominguez and Reyes, 2009).
Therefore, it is plausible that SUMO has
a more active role in the transcriptional
repression functions of IkBa than is pro-
posed here.
This report adds to the growing catalog
of alternative functions for components of
the NF-kB/IkB/IKK signaling pathway
(Perkins, 2012) and, increasingly, the
paradigm of a series of linear events
leading from receptor-mediated signaling
to NF-kB translocation to the nucleus,
appears to be an over-simplification. To
this list can be added nuclear, NF-kB
independent, transcriptional regulation
by IkBa, which not only links the activity
of this pathway to the Polycomb tran-
scriptional regulators but also may servelsevier Inc.as a fundamental mechanism controlling
skin homeostasis and tumorigenesis.
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